Information services provider Thomson Reuters, US, has announced that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, pharmaceutical and academic organisations find partnering opportunities worldwide.
The Outpartnering Registry is freely available to all organisations with drugs in development. It enables authorised users to share essential information about their company and drug pipeline with potential partners. Ninety percent of the world's top 50 pharmaceutical companies will have access to information in the registry via Thomson Pharma Partnering, the leading source of pipeline intelligence.
The Outpartnering Registry allows organisations to indicate which of their programmes and drugs are available for partnering and, optionally, what type of partnership they are seeking in which regions of the world; add and update partnering contacts together with links to LinkedIn profiles; and display attendance at partnering conferences and increase networking opportunities.
Search for more pharma related information
